List view / Grid view
The US National Institute of Allergy and Infectious Diseases (NIAID) plan outlines four research priorities, including furthering understanding of SARS-CoV-2 viral transmission and pathogenesis and development of animal models.
Professor Saad Shakir explains why cytokine storms occur in COVID-19 patients and suggests potential therapies for the symptoms of the coronavirus.
An international group of researchers has revealed that goblet and ciliated cells in the nose have high levels of the entry proteins for the SARS-CoV-2 coronavirus.
Professor Yehuda Shoenfeld suggests hyperferritinaemia, a condition caused by high ferritin levels, may be causing the severe COVID-19 symptoms.
Peptides could serve as a potential platform for development of novel drugs for the treatment of the COVID-19 coronavirus.
Exceptions to high quality research should not be made simply because of the COVID-19 pandemic, argue scientists in a new commentary.
The UK National Institute of Health Research (NIHR) and UK Research and Innovation (UKRI) wish to fund research exploring if people from black, Asian and middle eastern backgrounds are disproportionately at risk from COVID-19.
Histone deacetylase 2 (HDAC2) plays a key role in the regulation of inflammatory response in monocytes so could be a target for COVID-19, argue Dr Rosa Maria Tordera and Maria Cortes.
Ali Shilatifard’s article explains how investment in institutes performing molecular research is essential, as it is the foundation for all attempts to combat COVID-19 and other future pandemics.
Researchers have found a lead compound which they say inhibits SARS-CoV-2 viral replication and demonstrates good pharmacokinetic activity in vivo.
Scientists from Singapore have argued that T-cell immunotherapy can be used to combat a range of infectious diseases, including COVID-19.
A new study has revealed that less than 10 percent of respiratory and intestinal cells are susceptible to SARS-CoV-2 infection and expression of ACE2 receptors is driven by the body's immune response.
Glycomimetics, a novel class of antivirals, prevented influenza, herpes viruses and papillomaviruses from infecting cells in animal models and could show similar efficacy against COVID-19.
A study has shown that the COVID-19 pandemic has resulted in a high level of research donations, making the condition the third most funded disease on average by year.
The developers of a novel method to create immunological assay probes for screening T cells has leveraged their new protocol against COVID-19.
